Answers to Your Questions: Can Hidradenitis Suppurativa Cause Joint Pain?
Table of Contents
Introduction Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and sinus tracts that typically develop in areas such as the underarms, groin, and buttocks (Sartorius et al., 2017). While HS is primarily recognized as a skin disorder, its systemic effects are often overlooked. One question frequently asked by patients is whether HS can lead to joint pain. The answer involves understanding the interplay between chronic inflammation, immune dysregulation, and associated comorbidities (Sabin et al., 2020).
At EliteAyurveda, we take a holistic approach to managing HS, addressing not only the visible symptoms but also the underlying systemic imbalances that contribute to complications like joint pain.
Can Hidradenitis Suppurativa Cause Joint Pain?
Understanding the Link Between HS and Joint Pain
1. Chronic Inflammation and Immune Dysregulation
How It Works: HS is an inflammatory disease involving overactivity of the immune system (Jfri et al., 2019). Chronic inflammation does not remain confined to the skin but can affect other parts of the body, including the joints.
Outcome: Prolonged inflammation can lead to pain, swelling, and stiffness in the joints, a condition resembling inflammatory arthritis (Kumar et al., 2016).
2. Shared Comorbidities
Obesity and Metabolic Syndrome: These conditions, frequently associated with HS, increase the risk of joint-related issues due to excess mechanical stress and systemic inflammation (Egeberg et al., 2016).
Arthritis Connection: Studies show a higher prevalence of inflammatory arthritis, particularly spondyloarthritis, in individuals with HS (Fimmel & Zouboulis, 2020).
3. Autoimmune and Autoinflammatory Mechanisms
Immune Dysregulation: Both HS and conditions like psoriatic arthritis share similar immune pathways, suggesting a potential link (Giamarellos-Bourboulis et al., 2016).
Joint Pain in HS Patients: Some individuals may develop joint pain as part of an overarching autoinflammatory syndrome, even without a formal arthritis diagnosis (van der Zee & Prens, 2011).
4. Side Effects of Medications
Conventional HS Treatments: Long-term use of corticosteroids or biologics can occasionally contribute to joint discomfort as a side effect, either through bone density loss or changes in the immune response (Kimball et al., 2018).
How Joint Pain Manifests in HS Patients
Localized Pain: Pain limited to specific joints, often related to adjacent HS lesions or inflammation in nearby tissues (Mendes et al., 2019).
Generalized Arthritis: Symptoms resembling autoimmune arthritis, such as morning stiffness, joint swelling, and fatigue (van der Zee & Prens, 2011).
Reactive Pain: Pain resulting from altered gait or posture due to HS-related discomfort, leading to stress on the joints (Kumar et al., 2016).
Ayurvedic Insights on HS and Joint Pain
In Ayurveda, HS can be considered a manifestation of doshic imbalances, primarily involving aggravated Pitta (heat and inflammation) and Kapha (blockages and swelling) (Lad, 2002). Joint pain associated with HS may arise from:
Accumulated Ama (Toxins): Poor digestion and metabolic imbalances lead to toxin buildup, which settles in the joints and exacerbates inflammation (Pole, 2013).
Vata Aggravation: The dosha responsible for movement, when imbalanced, can cause joint stiffness, pain, and degeneration (Frawley, 2000).
Systemic Imbalance: The immune and digestive systems are interconnected in Ayurveda, and disturbances contribute to both skin and joint symptoms (Sharma et al., 2013).
Our Ayurvedic Approach to Managing HS and Joint Pain
At EliteAyurveda, we take a personalized, holistic approach to address both HS and associated joint pain.
1. Detoxification (Shodhana)
Purpose: Eliminate toxins from the body to reduce inflammation and improve joint and skin health (Sharma et al., 2013).
Approach: Specialized external Ayurvedic therapies and internal detoxification protocols target the root cause of inflammation.
2. Personalized Herbal Medications
For Joint Pain: Herbal formulations designed to balance Vata and reduce inflammation in the joints (Lad, 2002).
For HS: Herbs that support immune modulation, detoxification, and skin healing (Pole, 2013).
3. Diet and Lifestyle Modifications
Anti-Inflammatory Diet: Emphasis on cooling, anti-inflammatory foods to pacify Pitta, such as leafy greens, turmeric, and hydrating fluids (Frawley, 2000).
Avoiding Triggers: Eliminating spicy, oily, and processed foods that aggravate inflammation (Lad, 2002).
Stress Reduction: Incorporating mindfulness, yoga, and breathing exercises to reduce systemic stress and inflammation (Sharma et al., 2013).
4. Strengthening Digestive Health
Enhancing Agni (Digestive Fire): Strengthening digestion prevents toxin buildup, which contributes to both skin and joint symptoms (Pole, 2013).
Probiotic Support: Ayurvedic dietary practices and fermented foods support gut health, which is closely tied to inflammation regulation (Frawley, 2000).
Case Study: Integrated Management of HS and Joint Pain
Patient Profile:
Age: 39
Symptoms: Painful HS lesions in the groin and underarms, stiffness in the knees and lower back.
Medical History: Diagnosed with metabolic syndrome and intermittent joint pain.
Treatment Plan:
Detoxification: Weekly therapies to cleanse the blood and remove toxins (Sharma et al., 2013).
Herbal Medications: Personalized formulations to balance Pitta and Vata doshas (Lad, 2002).
Dietary Changes: Anti-inflammatory diet with a focus on cooling, hydrating foods (Frawley, 2000).
Yoga Therapy: Gentle yoga poses to reduce stress on the joints and improve flexibility (Pole, 2013).
Outcome:
Significant reduction in skin inflammation within 2 months.
Joint stiffness and pain decreased by 70% within 3 months.
Sustained improvement with no flare-ups after 6 months of consistent Ayurvedic care.
From the Doctor’s Desk: Key Takeaways
Joint Pain is Not Uncommon in HS: Chronic inflammation and systemic involvement can lead to joint-related symptoms (Sabin et al., 2020).
Holistic Care is Essential: Managing both HS and joint pain requires addressing the root causes, not just the symptoms (Sharma et al., 2013).
Ayurveda Offers Sustainable Relief: By focusing on detoxification, immune modulation, and dosha balance, Ayurveda provides a natural path to healing (Lad, 2002).
Conclusion
Hidradenitis suppurativa (HS) is a skin disorder that causes inflammation. There are numerous inflammatory illnesses. Many people share similar characteristics and may be connected.
The presence of HS raises the likelihood of acquiring another inflammatory illness. People with HS are more likely to develop various forms of arthritis. Metabolic syndrome and Crohn’s disease are two other inflammatory disorders.
Joint pain associated with Hidradenitis Suppurativa is a reminder of the systemic nature of this chronic condition. While conventional treatments may provide temporary relief, Ayurveda offers a holistic, root-cause approach to managing both HS and its associated symptoms (Sharma et al., 2013). By addressing dosha imbalances, improving digestion, and supporting the immune system, EliteAyurveda empowers patients to achieve lasting relief and improved quality of life.
Talk to your healthcare staff if you observe any changes in your health. Early detection is critical.
2. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35(2 pt 1):191-194. [DOI] [PubMed] [Google Scholar]
3. Shahi V, Alikhan A, Vazquez BG, Weaver AL, Davis MD. Prevalence of hidradenitis suppurativa: a population-based study in Olmsted County, Minnesota. Dermatology. 2014;229:154-158. [DOI] [PMC free article] [PubMed] [Google Scholar]
4. Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133:1506-1511. [DOI] [PubMed] [Google Scholar]
5. Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: an update. J Am Acad Dermatol. 2015;73(5 suppl 1):S8-S11. [DOI] [PubMed] [Google Scholar]
6. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62:205-217. [DOI] [PubMed] [Google Scholar]
7. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165:391-398. [DOI] [PubMed] [Google Scholar]
8. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60:539-561. [DOI] [PubMed] [Google Scholar]
9. Miller IM, Ellervik C, Vinding GR, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014;150:1273-1280. [DOI] [PubMed] [Google Scholar]
10. Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C. Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149:762-764. [DOI] [PubMed] [Google Scholar]
11. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)—a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409-415. [DOI] [PubMed] [Google Scholar]
12. Marzano AV, Menicanti C, Crosti C, Trevisan V. Neutrophilic dermatoses and inflammatory bowel diseases. G Ital Dermatol Venereol. 2013;148:185-196. [PubMed] [Google Scholar]
13. Van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol. 2010;162:195-197. [DOI] [PubMed] [Google Scholar]
14. Soukiasian S, Foster S. Diagnostic Problems in Clinical Ophthalmology. Philadelphia, PA: Saunders; 1994:220-226. [Google Scholar]
15. Wang B, Yang W, Wen W, et al. Gamma-secretase gene mutations in familial acne inversa. Science. 2010;330:1065. [DOI] [PubMed] [Google Scholar]
16. Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity. 2010;32:14-27. [DOI] [PubMed] [Google Scholar]
17. Roux CH, Saraux A, Le Bihan E, et al. Rheumatoid arthritis and spondyloarthropathies: geographical variations in prevalence in France. J Rheumatol. 2007;34:117-122. [PubMed] [Google Scholar]
18. Richette P, Molto A, Viguier M, et al. Hidradenitis suppurativa associated with spondyloarthritis—results from a multicenter national prospective study. J Rheumatol. 2014;41:490-494. [DOI] [PubMed] [Google Scholar]
19. Rosner IA, Richter DE, Huettner TL, Kuffner GH, Wisnieski JJ, Burg CG. Spondyloarthropathy associated with hidradenitis suppurativa and acne conglobate. Ann Intern Med. 1982;97:520-525. [DOI] [PubMed] [Google Scholar]
20. Bhalla R, Sequeria W. Arthritis associated with hidradenitis suppurativa. Ann Rheum Dis. 1994;53:64-77. [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Saraceno R, Babino G, Chiricozzi A, Zangrilli A, Chimenti S. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition. J Am Acad Dermatol. 2015;72:e42-e44. [DOI] [PubMed] [Google Scholar]
22. Thein M, Hogarth MB, Acland K. Seronegative arthritis associated with the follicular occlusion triad. Clin Exp Dermatol. 2004;29:550-552. [DOI] [PubMed] [Google Scholar]
23. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradenitis suppurativa with adalimumab. J Am Acad Dermatol. 2006;55:163-164. [DOI] [PubMed] [Google Scholar]
